Iloperidone + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post Traumatic Stress Disorder
Conditions
Post Traumatic Stress Disorder
Trial Timeline
Jul 1, 2013 → Feb 1, 2014
NCT ID
NCT01917318About Iloperidone + Placebo
Iloperidone + Placebo is a phase 2 stage product being developed by Novartis for Post Traumatic Stress Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT01917318. Target conditions include Post Traumatic Stress Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Post Traumatic Stress Disorder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01917318 | Phase 2 | Terminated |
| NCT01464229 | Approved | Completed |
Competing Products
20 competing products in Post Traumatic Stress Disorder